New dose strategy aims to cut bleeding in cancer patients on blood thinners

NCT ID NCT06886516

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a specially adjusted dose of the blood thinner apixaban can safely treat blood clots in cancer patients who also have low platelet counts. About 30 adults with active cancer and a recent clot will receive the adjusted dose. The goal is to see if this approach reduces bleeding while still preventing new clots.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEEP VEIN THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism thrombocytopenia Thromboembolism thrombotic disease venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact